APOE genotype-dependent modulation of astrocyte chemokine CCL3 production

GLIA

Volumn 63, Issue 1, 2015, Pages 51-65

  Cudaback, Eiron ^a   Yang, Yue ^a   Montine, Thomas J ^a   Keene, C Dirk ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alzheimer's disease; APOE; Astrocytes; Chemokine; Neuroinflammation

Indexed keywords

APOLIPOPROTEIN E; CARBON TETRACHLORIDE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; AMYLOID BETA PROTEIN;

ANIMAL CELL; ARTICLE; ASTROCYTE; ASTROCYTE CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; GENE EXPRESSION; GENETIC RISK; GENOTYPE; HUMAN; HUMAN CELL; INNATE IMMUNITY; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ALZHEIMER DISEASE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; GENETICS; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEINS E; ASTROCYTES; CELLS, CULTURED; CHEMOKINE CCL3; GENOTYPE; HUMANS; MICE, INBRED C57BL; MICROGLIA;

EID: 84911984944     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22732     Document Type: Article

References (95)

1. Aguzzi A, Barres BA, Bennett ML. 2013. Microglia: scapegoat, saboteur, or something else? Science 339:156-161.
2. Ahamed J, Venkatesha RT, Thangam EB, Ali H. 2004. C3a enhances nerve growth factor-induced NFAT activation and chemokine production in a human mast cell line, HMC-1. J Immunol 172:6961-6968.
3. Azizi G, Khannazer N, Mirshafiey A. 2014. The potential role of chemokines in Alzheimer's Disease pathogenesis. Am J Alzheimers Dis Other Demen 29:415-425.
4. Babcock AA, Kuziel WA, Rivest S, Owens T. 2003. Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci 23:7922-7930.
5. Balashov KE, Rottman JB, Weiner HL, Hancock WW. 1999. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 96:6873-6878.
6. Benfenati V, Caprini M, Dovizio M, Mylonakou MN, Ferroni S, Ottersen OP, Amiry-Moghaddam M. 2011. An aquaporin-4/transient receptor potential vanilloid 4 (AQP4/TRPV4) complex is essential for cell-volume control in astrocytes. Proc Natl Acad Sci USA 108:2563-2568.
7. Bsibsi M, Persoon-Deen C, Verwer RW, Meeuwsen S, Ravid R, Van Noort JM. 2006. Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. Glia 53:688-695.
8. Cameron B, Tse W, Lamb R, Li X, Lamb BT, Landreth GE. 2012. Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease. J Neurosci 32:15112-15123.
9. Carrero I, Gonzalo MR, Martin B, Sanz-Anquela JM, Arevalo-Serrano J, Gonzalo-Ruiz A. 2012. Oligomers of beta-amyloid protein (Abeta1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1beta, tumour necrosis factor-alpha, and a nuclear factor kappa-B mechanism in the rat brain. Exp Neurol 236:215-227.
10. Chui R, Dorovini-Zis K. 2010. Regulation of CCL2 and CCL3 expression in human brain endothelial cells by cytokines and lipopolysaccharide. J Neuroinflammation 7:1.
11. Cimino PJ, Sokal I, Leverenz J, Fukui Y, Montine TJ. 2009. DOCK2 is a microglial specific regulator of central nervous system innate immunity found in normal and Alzheimer's disease brain. Am J Pathol 175:1622-1630.
12. Conductier G, Blondeau N, Guyon A, Nahon JL, Rovere C. 2010. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 224:93-100.
13. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ and others. 2012. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335:1503-1506.
14. Cross AK, Woodroofe MN. 1999. Chemokines induce migration and changes in actin polymerization in adult rat brain microglia and a human fetal microglial cell line in vitro. J Neurosci Res 55:17-23.
15. Cudaback E, Li X, Montine KS, Montine TJ, Keene CD. 2011. Apolipoprotein E isoform-dependent microglia migration. FASEB J 25:2082-2091.
16. Cudaback E, Li X, Yang Y, Yoo T, Montine KS, Craft S, Montine TJ, Keene CD. 2012. Apolipoprotein C-I is an APOE genotype-dependent suppressor of glial activation. J Neuroinflammation 9:192.
17. Cui W, Sun Y, Wang Z, Xu C, Peng Y, Li R. 2012. Liver X receptor activation attenuates inflammatory response and protects cholinergic neurons in APP/PS1 transgenic mice. Neuroscience 210:200-210.
18. Das M, Mohapatra S, Mohapatra SS. 2012. New perspectives on central and peripheral immune responses to acute traumatic brain injury. J Neuroinflammation 9:236.
19. Eisenberg DT, Kuzawa CW, Hayes MG. 2010. Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history. Am J Phys Anthropol 143:100-111.
20. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD. 2007. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13:432-438.
21. Evans MC, Couch Y, Sibson N, Turner MR. 2012. Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci 53:34-41.
22. Festoff BW, Ameenuddin S, Arnold PM, Wong A, Santacruz KS, Citron BA. 2006. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 97:1314-1326.
23. Flex A, Giovannini S, Biscetti F, Liperoti R, Spalletta G, Straface G, Landi F, Angelini F, Caltagirone C, Ghirlanda G, Bernabei R. 2014. Effect of proinflammatory gene polymorphisms on the risk of Alzheimer's disease. Neurodegener Dis 13:230-236.
24. Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W. 2011. Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis 2:e167.
25. Geppert AM, Losy J, Przedpelska-Ober E, Kozubski W. 2010. CCL3 correlates with the number of mood disturbances and personality changes in patients with Alzheimer's disease. Psychiatry Res 176:261-264.
26. Gonzalez-Perez O, Gutierrez-Fernandez F, Lopez-Virgen V, Collas-Aguilar J, Quinones-Hinojosa A, Garcia-Verdugo JM. 2012. Immunological regulation of neurogenic niches in the adult brain. Neuroscience 226:270-281.
27. Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE. 2013. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78:631-643.
28. Halassa MM, Haydon PG. 2010. Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu Rev Physiol 72:335-355.
29. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schürmann B, Heun R, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J. 2009. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41:1088-1093.
30. Holtzman DM, Herz J, Bu G. 2012. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2:a006312.
31. Howell OW, Rundle JL, Garg A, Komada M, Brophy PJ, Reynolds R. 2010. Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis. J Neuropathol Exp Neurol 69:1017-1033.
32. Israelsson C, Bengtsson H, Kylberg A, Kullander K, Lewen A, Hillered L, Ebendal T. 2008. Distinct cellular patterns of upregulated chemokine expression supporting a prominent inflammatory role in traumatic brain injury. J Neurotrauma 25:959-974.
33. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. 2008. ApoE promotes the proteolytic degradation of Abeta. Neuron 58:681-693.
34. Kalkonde YV, Morgan WW, Sigala J, Maffi SK, Condello C, Kuziel W, Ahuja SS, Ahuja SK. 2007. Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration. Brain Res 1128:1-11.
35. Keene CD, Cudaback E, Li X, Montine KS, Montine TJ. 2011. Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease. Curr Opin Neurobiol 21:920-928.
36. Kelly ME, Clay MA, Mistry MJ, Hsieh-Li HM, Harmony JA. 1994. Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell Immunol 159:124-139.
37. Kim B, Jeong HK, Kim JH, Lee SY, Jou I, Joe EH. 2011. Uridine 5'-diphosphate induces chemokine expression in microglia and astrocytes through activation of the P2Y6 receptor. J Immunol 186:3701-3709.
38. Kiyota T, Gendelman HE, Weir RA, Higgins EE, Zhang G, Jain M. 2013. CCL2 affects beta-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease. Neurobiol Aging 34:1060-1068.
39. Klegeris A, McGeer EG, McGeer PL. 2007. Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol 20:351-357.
40. LaDu MJ, Shah JA, Reardon CA, Getz GS, Bu G, Hu J, Guo L, Van Eldik LJ. 2001. Apolipoprotein E and apolipoprotein E receptors modulate A beta-induced glial neuroinflammatory responses. Neurochem Int 39:427-434.
41. Laskowitz DT, Goel S, Bennett ER, Matthew WD. 1997. Apolipoprotein E suppresses glial cell secretion of TNF alpha. J Neuroimmunol 76:70-74.
42. Leiserson WM, Forbush B, Keshishian H. 2011. Drosophila glia use a conserved cotransporter mechanism to regulate extracellular volume. Glia 59:320-332.
43. Levine AJ, Singer EJ, Sinsheimer JS, Hinkin CH, Papp J, Dandekar S, Giovanelli A, Shapshak P. 2009. CCL3 genotype and current depression increase risk of HIV-associated dementia. Neurobehav HIV Med 1:1-7.
44. Li K, Dai D, Yao L, Gu X, Luan K, Tian W, Zhao Y, Wang B. 2008. Association between the macrophage inflammatory protein-l alpha gene polymorphism and Alzheimer's disease in the Chinese population. Neurosci Lett 433:125-128.
45. Lynch JR, Morgan D, Mance J, Matthew WD, Laskowitz DT. 2001. Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J Neuroimmunol 114:107-113.
46. Maezawa I, Maeda N, Montine TJ, Montine KS. 2006a. Apolipoprotein E-specific innate immune response in astrocytes from targeted replacement mice. J Neuroinflammation 3:10.
47. Maezawa I, Nivison M, Montine KS, Maeda N, Montine TJ. 2006b. Neurotoxicity from innate immune response is greatest with targeted replacement of E4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK. FASEB J 20:797-799.
48. Maezawa I, Zimin PI, Wulff H, Jin LW. 2011. Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem 286:3693-3706.
49. Malm TM, Magga J, Kuh GF, Vatanen T, Koistinaho M, Koistinaho J. 2008. Minocycline reduces engraftment and activation of bone marrow-derived cells but sustains their phagocytic activity in a mouse model of Alzheimer's disease. Glia 56:1767-1779.
50. Man SM, Ma YR, Shang DS, Zhao WD, Li B, Guo DW, Fang WG, Zhu L, Chen YH. 2007. Peripheral T cells overexpress MIP-1alpha to enhance its transendothelial migration in Alzheimer's disease. Neurobiol Aging 28:485-496.
51. Mandrekar-Colucci S, Karlo JC, Landreth GE. 2012. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci 32:10117-10128.
52. Mayer TZ, Simard FA, Cloutier A, Vardhan H, Dubois CM, McDonald PP. 2013. The p38-MSK1 signaling cascade influences cytokine production through CREB and C/EBP factors in human neutrophils. J Immunol 191:4299-4307.
53. McGeer PL, Rogers J, McGeer EG. 2006. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis 9:271-276.
54. Medeiros R, LaFerla FM. 2013. Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol 239:133-138.
55. Mines M, Ding Y, Fan GH. 2007. The many roles of chemokine receptors in neurodegenerative disorders: emerging new therapeutical strategies. CurrMedChem 14:2456-2470.
56. Mulligan SJ, MacVicar BA. 2004. Calcium transients in astrocyte endfeet cause cerebrovascular constrictions. Nature 431:195-199.
57. Neumann J, Gunzer M, Gutzeit HO, Ullrich O, Reymann KG, Dinkel K. 2006. Microglia provide neuroprotection after ischemia. FASEB J 20:714-716.
58. Nolan YM, Sullivan AM, Toulouse A. 2013. Parkinson's disease in the nuclear age of neuroinflammation. Trends Mol Med 19:187-196.
59. Okamura T, Katayama T, Obinata C, Iso Y, Chiba Y, Kobayashi H, Yamada Y, Harashima H, Minami M. 2012. Neuronal injury induces microglial production of macrophage inflammatory protein-1alpha in rat corticostriatal slice cultures. J Neurosci Res 90:2127-2133.
60. Perea G, Araque A. 2010. GLIA modulates synaptic transmission. Brain Res Rev 63:93-102.
61. Peterson PK, Hu S, Salak-Johnson J, Molitor TW, Chao CC. 1997. Differential production of and migratory response to beta chemokines by human microglia and astrocytes. J Infect Dis 175:478-481.
62. Prokop S, Miller KR, Heppner FL. 2013. Microglia actions in Alzheimer's disease. Acta Neuropathol 126:461-477.
63. Qin S, Colin C, Hinners I, Gervais A, Cheret C, Mallat M. 2006. System Xc- and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1-40. J Neurosci 26:3345-3356.
64. Redell JB, Moore AN, Grill RJ, Johnson D, Zhao J, Liu Y, Dash PK. 2012. Analysis of functional pathways altered after mild traumatic brain injury. J Neurotrauma 30:752-764.
65. Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, Xu L, Aschmies S, Kirksey Y, Hu Y, Wagner E, Parratt A, Xu J, Li Z, Zaleska MM, Jacobsen JS, Pangalos MN, Reinhart PH. 2008. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci 28:11445-11453.
66. Seabrook TJ, Jiang L, Maier M, Lemere CA. 2006. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 53:776-782.
67. Seifert G, Schilling K, Steinhauser C. 2006. Astrocyte dysfunction in neurological disorders: a molecular perspective. Nat Rev Neurosci 7:194-206.
68. Shiratori M, Tozaki-Saitoh H, Yoshitake M, Tsuda M, Inoue K. 2010. P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways. J Neurochem 114:810-819.
69. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. 1998. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 84:238-249.
70. Soares DM, Ott D, Melo MC, Souza GE, Roth J. 2013. Chemokine ligand (CCL)-3 promotes an integrated febrile response when injected within pre-optic area (POA) of rats and induces calcium signaling in cells of POA microcultures but not TNF-alpha or IL-6 synthesis. Brain Behav Immun 34:120-129.
71. Suh SW, Bergher JP, Anderson CM, Treadway JL, Fosgerau K, Swanson RA. 2007. Astrocyte glycogen sustains neuronal activity during hypoglycemia: studies with the glycogen phosphorylase inhibitor CP-316, 819 ([R-R*, S*]-5-chloro-N-[2-hydroxy-3-(methoxymethylamino)-3-oxo-1-(phenylmethyl)pro pyl]-1H-indole-2-carboxamide). J Pharmacol Exp Ther 321:45-50.
72. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N. 1997. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 272:17972-17980.
73. Takami S, Nishikawa H, Minami M, Nishiyori A, Sato M, Akaike A, Satoh M. 1997. Induction of macrophage inflammatory protein MIP-1alpha mRNA on glial cells after focal cerebral ischemia in the rat. Neurosci Lett 227:173-176.
74. Takano T, Tian GF, Peng W, Lou N, Libionka W, Han X, Nedergaard M. 2006. Astrocyte-mediated control of cerebral blood flow. Nat Neurosci 9:260-267.
75. Terwel D, Steffensen KR, Verghese PB, Kummer MP, Gustafsson JA, Holtzman DM, Heneka MT. 2011. Critical role of astroglial apolipoprotein E and liver X receptor-alpha expression for microglial Abeta phagocytosis. J Neurosci 31:7049-7059.
76. Tourdias T, Dousset V. 2012. Neuroinflammatory imaging biomarkers: relevance to multiple sclerosis and its therapy. Neurotherapeutics 10:111-123.
77. Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, Mahan TE, Landreth GE, Castellano JM, Jiang H, Cirrito JR, Holtzman DM. 2013. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener 8:13.
78. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. 2002. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 13:1067-1070.
79. Vitek MP, Brown CM, Colton CA. 2009. APOE genotype-specific differences in the innate immune response. Neurobiol Aging 30:1350-1360.
80. Wang H, Christensen DJ, Vitek MP, Sullivan PM, Laskowitz DT. 2009. APOE genotype affects outcome in a murine model of sepsis: implications for a new treatment strategy. Anaesth Intensive Care 37:38-45.
81. West HL, Rebeck GW, Hyman BT. 1994. Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease. Neurosci Lett 175:46-48.
82. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S. 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22:1763-1771.
83. Xu PT, Schmechel D, Rothrock-Christian T, Burkhart DS, Qiu HL, Popko B, Sullivan P, Maeda N, Saunders AM, Roses AD, Gilbert JR. 1996. Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. Neurobiol Dis 3:229-245.
84. Xue D, Zhao M, Wang YJ, Wang L, Yang Y, Wang SW, Zhang R, Zhao Y, Liu RT. 2012. A multifunctional peptide rescues memory deficits in Alzheimer's disease transgenic mice by inhibiting Abeta42-induced cytotoxicity and increasing microglial phagocytosis. Neurobiol Dis 46:701-709.
85. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT. 2012. PPARgamma/RXRalpha-induced and CD36-mediated microglial amyloid-beta phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci 32:17321-17331.
86. Yan C, Wu M, Cao J, Tang H, Zhu M, Johnson PF, Gao H. 2012a. Critical role for CCAAT/enhancer-binding protein beta in immune complex-induced acute lung injury. J Immunol 189:1480-1490.
87. Yan C, Zhu M, Staiger J, Johnson PF, Gao H. 2012b. C5a-regulated CCAAT/enhancer-binding proteins beta and delta are essential in Fcgamma receptor-mediated inflammatory cytokine and chemokine production in macrophages. J Biol Chem 287:3217-3230.
88. Yang Y, Cudaback E, Jorstad NL, Hemingway JF, Hagan CE, Melief EJ, Li X, Yoo T, Khademi SB, Montine KS, Montine TJ, Keene CD. 2013. APOE3, but not APOE4, bone marrow transplantation mitigates behavioral and pathological changes in a mouse model of Alzheimer disease. Am J Pathol 183:905-917.
89. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. 1998. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 95:15769-15774.
90. Yu CE, Seltman H, Peskind ER, Galloway N, Zhou PX, Rosenthal E, Wijsman EM, Tsuang DW, Devlin B, Schellenberg GD. 2007. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association. Genomics 89:655-665.
91. Zhang-Gandhi CX, Drew PD. 2007. Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes. J Neuroimmunol 183:50-59.
92. Zhong N, Weisgraber KH. 2009. Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. J Biol Chem 284:6027-6031.
93. Zhu Y, Kodvawala A, Hui DY. 2010. Apolipoprotein E inhibits toll-like receptor (TLR)-3- and TLR-4-mediated macrophage activation through distinct mechanisms. Biochem J 428:47-54.
94. Zhu Y, Nwabuisi-Heath E, Dumanis SB, Tai LM, Yu C, Rebeck GW, LaDu MJ. 2012. APOE genotype alters glial activation and loss of synaptic markers in mice. Glia 60:559-569.
95. Zonta M, Angulo MC, Gobbo S, Rosengarten B, Hossmann KA, Pozzan T, Carmignoto G. 2003. Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat Neurosci 6:43-50.